India, April 28 -- Artelo Biosciences, Inc. (ARTL), a clinical-stage pharmaceutical company, announced positive effects of ART26.12 in both in vitro and in vivo psoriasis models, showing results comparable to immunomodulatory drugs with known serious adverse events.
ART26.12 is Artelo's orally active, small-molecule inhibitor of Fatty Acid Binding Protein 5 or FABP5. ART26.12 is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. Data from the first Phase 1 trial with ART26.12 is anticipated in the second quarter.
The new research was published in the peer-reviewed Journal of Investigative Dermatology. The research article, titled ART26.12, A FATTY ACID-BINDING PROTEIN 5 INHIBITOR, SHOWS EFFICACY IN PRECL...